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Abstract
Background: Rituximab is widely used in kidney transplantation. However, it is not clear whether the conventional
doses of maintenance immunosuppressant in rituximab-treated kidney transplantation (KT) are appropriate. In our
previous study, decreasing mycophenolate mofetil (MMF) dose due to infection did not increase the incidence of
rejection or graft failure. Based on these experiences, we developed a new protocol with a lower dose of MMF and
studied its clinical outcomes in rituximab-treated KT.
Methods: We enrolled all patients who underwent ABO-incompatible or human leukocyte antigen (HLA)-sensitized
living donor KT with the new immunosuppressant protocol after preconditioning with rituximab, but without
splenectomy from November 2011 to May 2013. Seventy-two patients (group 1) were consecutively enrolled in this
study and followed until November 2013. Patients from our previous study served as control groups. Sixty-seven
patients received KT using rituximab with a conventional dose of MMF (group 2), and 87 patients received ABO
compatible KT without need for rituximab (group 3). Clinical outcomes, including rejection, infection, and graft
survival, were compared between the groups. The χ2 test and Fisher’s exact test were used for categorical variables,
the Student’s t-test and Mann-Whitney U test were used for continuous variables, and a log-rank test was used for
mortality analysis.
Results: Doses of postoperative MMF (g/day) were lower in group 1 than in the other groups (1.03 ± 0.19, 1.48 ± 0.34
and 1.48 ± 0.32 g/day at 1 week, p < 0.001). Infectious complications occurred more often in groups with conventional
MMF doses (group 2 and 3) than in group 1 (16.7 vs. 37.3 %, p = 0.007 and 16.7 vs. 34.5 %, p = 0.012, respectively).
Notably, group 1 showed a lower incidence of cytomegalovirus infection than group 2. However, reduction in MMF
dose did not increase the incidence of acute rejection (4.2, 4.5 and 10.3 %). Only one graft failure occurred in group 2
due to vessel kinking after operation. There were no significant differences in the incidence of malignancy and
mortality between groups.
Conclusions: A low MMF dose reduces infection without increasing rejection or graft loss and it may be appropriate
to reduce the dose of MMF for rituximab-treated KT patients.
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Background
Rituximab, a chimeric anti-CD20 monoclonal antibody,
is widely used in desensitization protocols these days. It
was first used for ABO incompatible (ABOi) kidney
transplantation (KT) combined with plasmapheresis and
splenectomy in 2002 [1]. ABOi KT using rituximab in-
stead of splenectomy as a desensitization protocol was
reported within the following year [2]. Transplantations
in HLA sensitized patients have recently been performed
and ABOi/HLA-sensitized KT using rituximab has led
to successful results [3–5].
Some retrospective studies have reported that rituxi-
mab is associated with an increased risk of infectious
complications [6, 7]. However, a randomized, double-
blind, placebo-controlled study showed a trend toward
fewer and milder rejections during the first 6 months in
the rituximab group with no increase in infectious com-
plications [5]. In our previous study [8], serious infec-
tious complications occurred more often in the
rituximab-treated KT. Therefore, the doses of mycophe-
nolate mofetil (MMF) had to be decreased in the rituxi-
mab group to avoid or to cure serious infection.
However, acute rejection was not observed with the re-
duced doses of MMF. After these experiences, we chan-
ged our immunosuppressant protocol for ABOi KT and
HLA sensitized KT to a lower dose of MMF (1.0 g/day
after postoperative week 1 in advance), and collected
data prospectively without omitting any patients. So far,
no guidelines have been suggested for a safe and effect-
ive maintenance immunosuppressive regimen in rituxi-
mab- and IL-2-receptor antibody-treated KT.
In this study, we evaluated our protocol of low dose
of MMF in rituximab-treated KT, focusing on its as-
sociations with reduced infectious complications with-
out increased incidence of acute rejection.
Methods
Patients
We enrolled all patients who underwent ABOi or HLA-
sensitized, living-donor KT with the new immunosup-
pressant protocol after preconditioning with rituximab
but without splenectomy (group 1) at the Asan Medical
Center, a tertiary referral teaching hospital in Seoul,
Korea, from November 2011 to May 2013. Seventy-two
consecutive patients were enrolled for this study and
followed until November 2013. No patients were lost to
follow-up during the study period except in cases of
death. Patients received tacrolimus, MMF, and cortico-
steroids as maintenance immunosuppressants according
to the new protocol. Patients enrolled in our previous
study [8] served as controls. Of these, 67 patients re-
ceived desensitized KT using rituximab (group 2) and 87
patients received ABO compatible KT (group 3) between
January 2009 and May 2011. They all received
conventional doses of maintenance immunosuppres-
sants. This study was approved by Asan Medical Center
Institutional Review Board (2014–0724), and informed
consent was obtained from all participants.
Immunosuppression protocol
The new immunosuppressant protocol for rituximab-
treated renal transplantation is summarized in Fig. 1.
Tacrolimus, MMF, and steroids were used in addition to
rituximab and started 7–10 days before the operation.
Tacrolimus was started at a dose of 0.075 mg/kg bid,
and the target drug trough level was 10 ng/mL for post-
operative weeks 1–2 and 3–8 ng/mL thereafter. The
starting dose of MMF was 500 mg bid and elevated to
750 mg bid from day 0 to day 7 postoperatively. After
1 week, the dose of MMF was reduced to 500 mg bid. In
groups 2 and 3, the conventional dose of 1.5 g/day of
MMF was used for at least 1 month postoperatively. Ri-
tuximab was administered 7–10 days before the oper-
ation. We used 200 mg/body rituximab for ABOi living
donor transplantation, while 500 mg/body rituximab was
used in patients with a positive crossmatch on T-cell
flow cytometry. Basiliximab, an anti-CD25 monoclonal
antibody, was administered to all patients on the day of
the operation and on postoperative day 4. No patient re-
ceived splenectomy or intravenous immunoglobulin
(IVIG) injection. Several rounds of plasmapheresis were
performed until the ABO isoagglutinin titer was reduced
to less than 1:8 or T-cell flow cytometry (COBE® Spectra,
CaridianBCT, USA) was negative.
Diagnosis of rejection
Acute rejection was diagnosed on the basis of the Banff
criteria, and C4d staining was performed in all speci-
mens. Protocol biopsies were not routinely performed.
Renal biopsies were performed to confirm rejection
when clinically suspected by elevated serum creatinine.
Definition of infection
Cytomegalovirus (CMV) infection was defined as
positivity on a CMV antigenemia assay ≥50 cells/
200,000 white blood cells and treated with ganciclovir.
When plasma BK virus DNA was greater than 10,000
copies/ml, BK virus infection was diagnosed regardless
of nephropathy. The CMV antigenemia assay and BK
virus PCR were performed as previously reported, and
the definition of infection was the same as the previ-
ous study [8]. CMV prophylaxis was not performed
routinely because our nation-wide insurance system
supports oral valganciclovir prophylaxis only for a
case of donor’s CMV IgG is positive and recipient’s
CMV IgG is negative. Instead, we checked CMV anti-
genemia routinely at 1, 2, 3, 4, 6, 8, 12, 16, 20 and
24 weeks after KT and performed preemptive therapy
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[9]. All patients received oral trimethoprim/sulfameth-
oxazole (80/400 mg) for pneumocystis pneumonia
prophylaxis until 6 months post-operation.
Statistical analysis
Statistical analyses were performed with SPSS 21
(IBM Corp., Armonk, NY, USA). Data are expressed
as mean ± standard deviation or counts and percent-
ages. For categorical variables, the χ2 test and Fisher’s
exact test were used. Continuous variables were com-
pared using the Student’s t-test or Mann-Whitney U
test. Mortality rates were evaluated by the Kaplan-
Meier method with a log-rank test. All statistical tests




Seventy-two patients were enrolled in group 1 (re-
duced dose of MMF), and 67 and 87 patients were
enrolled in groups 2 and 3 (conventional dose of
MMF), respectively. The mean age was not signifi-
cantly different between groups 1 and 3, but group 2
patients were significantly older than group 1 patients
(40.92 ± 10.20 years vs. 44.88 ± 11.65 years, p = 0.034).
In addition, the donors of group 1 were younger than
the donors of group 3 (39.63 ± 10.95 vs. 43.00 ±
9.90 years, p = 0.043). There were more
glomerulonephritis-caused cases of end stage renal
disease in group 1. Most patients in all groups were
positive for CMV IgG, and the CMV IgG serostatus
of donor-recipient pairs was not different between
groups. The mean follow-up time was 14.89 ± 6.01,
12.63 ± 7.59, and 14.05 ± 8.17 months in groups 1–3,
respectively, without significant difference. Baseline
characteristics are summarized in Table 1.
Levels and doses of immunosuppressant
MMF doses were significantly lower in group 1 than
in group 3 (Table 2). However, MMF doses in group
1 were significantly lower compared with group 2,
predominantly in the early phase after transplantation,
as MMF doses in group 2 had to be decreased due to
infectious complications in many cases. Tacrolimus
levels were not different between groups post-
transplantation. The doses of methyl-prednisolone
were lower in group 1 than in group 2. However,
there was no difference between groups 1 and 3.
Incidence of infection
The incidence of infection was lower in group 1 than
in the other groups (Table 3). Although the incidence
of each infection (CMV, BKV infection, urinary tract
infection, pneumonia and sepsis) was not significantly
different between groups 1 and 3, the total incidence
was significantly lower in group 1. In addition, group
1 showed significantly lower incidence of CMV infec-
tion compared with group 2 (2.8 vs. 16.4 %, p =
0.007). Pneumonia and sepsis also showed trends of
lower incidence in group 1 than in group 2 (1.4 vs.
9.0 %, p = 0.056 and 0 vs. 6.0 %, p = 0.051,
respectively).
Graft rejection and serum creatinine levels
Acute cellular rejection occurred significantly more
often in group 3 than in group 1 (10.3 vs. 1.4 %, p =
0.023). There were no significant differences in other
types of graft rejection between groups 1 and 3
(Table 4). Hyperacute rejection did not occur in any
group. Chronic rejection occurred in a group 3 pa-
tient (0.6 %). There were 2 cases (2.8 %) of antibody-
mediated rejection in group 1. However, there were
no significant differences in rejection rates between
groups 1 and 2. Serum creatinine levels are summa-
rized in Table 5. Although there was no significant
Fig. 1 New immuonosuppressive protocol. Tacrolimus, mycophenolate mofetil (MMF) and steroids are used in addition to rituximab and started
7–10 days before the operation. Tacrolimus is started at a dose of 0.075 mg/kg bid, and the target drug trough level is 10 ng/mL for the first 2
postoperative weeks and 3–8 ng/mL after 2 weeks. MMF is started at a dose of 500 mg bid before the operation, and 750 mg bid is used for the
first postoperative week. After 1 week, MMF dose is reduced to 500 mg bid
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Table 1 Baseline clinical characteristics
Low dose MMF Conventional dose MMF p1a p2b
Rituximab(+) Rituximab(+) Rituximab(−)
Group 1 (n = 72) Group 2 (n = 67) Group 3 (n = 87)
Sex (male/female) 34/38 42/25 46/41 0.088 0.526
Age (years) 40.92 ± 10.20 44.88 ± 11.65 42.72 ± 10.39 0.034 0.273
Dialysis (hemo/peritoneal) 50/13 57/6 54/13 0.134 1.000
Dialysis duration (months) 24.95 ± 30.20 32.11 ± 33.47 31.04 ± 39.09 0.210 0.324
Etiology of ESRD 0.043 0.006
Diabetes mellitus 13 14 21
Hypertension 11 12 23
Glomerulonephritis 33 16 14
Vesicoureteral reflux 0 4 1
Polycystic kidney disease 3 5 5
Unknown etiology 11 11 15
Other causes 1 5 7
Past medical history
Diabetes mellitus 14 15 23 0.682 0.348
Hypertension 59 57 73 0.655 0.833
Hepatitis 4 6 2 0.522 0.411
Autoimmune disease 3 0 1 0.246 0.329
Malignancy history 1 3 0 0.352 0.453
Mean follow up time (months) 14.89 ± 6.01 12.63 ± 7.59 14.05 ± 8.17 0.053 0.455
ABO compatibility/T-flow 0.255
ABO incompatible 47 36 -
/T-flow(−)
ABO compatible 14 21 -
/T-flow(+)
ABO incompatible 11 10 -
/T-flow(+)
Donor to recipient 0.159
Compatible 14 21 87
A→ B 6 11 -
B→ A 9 8 -
A/B→O 24 18 -
AB→ A/B/O 19 9 -
HLA mismatch 3/7/13/14/10/19/6 4/0/7/20/7/18/11 4/2/12/25/14/19/11 0.065 0.335
(0/1/2/3/4/5/6)
HLA class I mismatch 5/14/25/16/12 4/5/27/14/17 5/8/34/23/17 0.260 0.441
(0/1/2/3/4/)
HLA class II mismatch 13/32/27 6/33/28 10/49/28 0.296 0.275
(0/1/2/)
Donor sex (male/female) 39/33 34/33 46/41 0.735 0.875
Donor age (years) 39.63 ± 10.95 41.88 ± 11.65 43.00 ± 9.90 0.241 0.043
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Table 1 Baseline clinical characteristics (Continued)
Donor’s relation with recipient 0.822 0.011
Parents 8 7 8
Siblings 17 20 36
Children 14 11 6
Spouse 27 21 22
Others 6 8 15
CMV IgG serostatus 0.178 0.590
Donor+/Recipient+ 70 (97.2 %) 65 (97.0 %) 86 (98.9 %)
Donor+/Recipient- 0 (0.0 %) 2 (3.0 %) 0 (0 %)
Donor-/Recipient+ 2 (2.8 %) 0 (0.0 %) 1 (1.1 %)
Abbreviations: CMV cytomegalovirus, ESRD end stage renal disease, HLA human leukocyte antigen, MMF mycophenolate mofetil
agroup 1 vs. group 2
bgroup 1 vs. group 3
Table 2 Doses of immunosuppressants
Low dose MMF Conventional dose MMF p1a p2b
Rituximab(+) Rituximab(+) Rituximab(−)
Group 1 Group 2 Group 3
(n = 72) (n = 67) (n = 87)
Tacrolimus drug levels (ng/ml)
Pre KT (72/67/87) 6.99 ± 2.57 9.56 ± 4.75 11.11 ± 6.58 <0.001 <0.001
After 1 month (72/65/87) 7.74 ± 3.53 9.17 ± 3.22 7.65 ± 2.89 0.015 0.847
After 3 months (71/55/86) 7.19 ± 2.79 7.64 ± 2.54 7.58 ± 2.76 0.349 0.380
After 6 months (71/48/71) 6.66 ± 2.50 7.11 ± 2.11 6.83 ± 2.19 0.304 0.664
After 1 year (49/39/48) 5.77 ± 1.81 6.57 ± 2.13 5.77 ± 2.16 0.060 0.987
After 2 years (6/4/15) 7.18 ± 1.28 5.48 ± 1.81 5.51 ± 3.16 0.116 0.228
Mycophenolate mofetil doses (g/day)
Pre KT (72/67/87) 1.44 ± 0.15 1.51 ± 0.29 1.55 ± 0.17 0.071 <0.001
After 1 week (72/66/87) 1.03 ± 0.19 1.48 ± 0.34 1.48 ± 0.32 <0.001 <0.001
After 2 weeks (72/66/87) 1.00 ± 0.15 1.42 ± 0.39 1.48 ± 0.31 <0.001 <0.001
After 3 weeks (72/66/87) 1.00 ± 0.17 1.39 ± 0.41 1.46 ± 0.32 <0.001 <0.001
After 1 month (72/65/87) 0.95 ± 0.24 1.26 ± 0.42 1.40 ± 0.39 <0.001 <0.001
After 3 months (71/55/86) 0.93 ± 0.30 1.14 ± 0.51 1.35 ± 0.38 0.007 <0.001
After 6 months (71/48/71) 0.94 ± 0.26 1.07 ± 0.50 1.24 ± 0.47 0.095 <0.001
After 1 year (49/39/47) 0.93 ± 0.28 0.88 ± 0.52 1.23 ± 0.41 0.637 <0.001
After 2 years (6/4/16) 1.08 ± 0.20 0.69 ± 0.55 1.28 ± 0.45 0.252 0.313
Methyl-prednisolone doses (mg/day)
Pre KT (72/67/87) 16.00 ± 0.00 16.84 ± 6.01 15.91 ± 0.86 0.259 0.365
After 1 month (72/65/87) 11.11 ± 1.68 11.97 ± 2.31 11.59 ± 2.70 0.015 0.195
After 3 months (71/55/86) 8.03 ± 1.49 9.09 ± 1.48 8.16 ± 2.06 <0.001 0.637
After 6 months (71/48/71) 6.25 ± 1.82 7.33 ± 1.39 6.87 ± 3.59 0.001 0.197
After 1 year (49/39/48) 4.61 ± 1.48 5.33 ± 1.80 5.96 ± 8.71 0.042 0.289
After 2 years (6/4/16) 3.00 ± 2.45 4.00 ± 0.00 3.75 ± 1.44 0.447 0.505
Abbreviations: KT kidney transplantation, MMF mycophenolate mofetil
agroup 1 vs. group 2
bgroup 1 vs. group 3
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difference between groups 1 and 3, serum creatinine
levels were lower in group 1 compared with group 2.
Incidence of malignancy and mortality
Malignancy occurred in 2 patients (3.0 %) in group 2
and 1 patient (1.1 %) in group 3, while there were no
cases of malignancy in group 1 (Table 6). There was
no significant difference in malignancy incidence be-
tween the groups. In group 2, malignancies were skin
squamous carcinoma and parathyroid cancer. In
group 3, one patient was diagnosed with colon cancer
at 23 months post-operation. One patient (1.4 %) in
group 1 died due to pneumonia aggravation, while
there were 3 deaths (4.5 %) in group 2 (Fig. 2) caused
by septic shock associated with urinary sepsis, uncon-
trollable fungal infective endocarditis and metabolic
acidosis of unknown origin. One death (1.1 %) caused
by pneumocystis pneumonia combined with bacterial
infection was reported in group 3. Graft failure oc-
curred in 1 patient in group 2 due to unexpected ves-
sel kinking after the operation.
Discussion
Our present study findings suggest that lower doses
of MMF can be safely used in rituximab-treated KT.
There was no increase in rejection in patients who
used low MMF doses, and infectious complications
occurred less frequently.
Cyclosporine, azathioprine and corticosteroid used
to be the maintenance immunosuppressants. However,
most groups now use tacrolimus, MMF and cortico-
steroid. More intense immunosuppression has in-
creased the concern about infections.
There have been various trials to reduce immuno-
suppressant levels. Typically, a dose of 375 mg/m2 or
500 mg/body rituximab is used in ABO incompatible
or HLA sensitized KT. However, good results have
been reported with lower doses of rituximab in ABOi
KT. Hiroki et al. [10] reduced the dose of rituximab
from 500 mg/body to 200 mg/body and compared
clinical outcomes and peripheral CD19 levels. Effect-
ive elimination of peripheral blood CD19 cells was
observed until 24 months after treatment. In addition,
there were no differences in creatinine levels, graft
loss, or CMV infection between the groups. Another
study compared the outcomes of ABO compatible
and ABOi KT using low doses of rituximab (100 mg/
m2) [11]. Estimated glomerular filtration rate, biopsy-
confirmed rejection episodes, acute antibody-mediated
rejection, and viral infection did not differ between
the groups. The 5-year patient survival rate was
100 % in both groups, while 5-year graft survival
rates were 95 % for ABO compatible and 100 % for
Table 3 Incidence of infection
Low dose MMF Conventional dose MMF p1a p2b
Rituximab(+) Rituximab(+) Rituximab(−)
Group 1 (n = 72) Group 2 (n = 67) Group 3 (n = 87)
Incidence of infection 12 (16.7 %) 25 (37.3 %) 30 (34.5 %) 0.007 0.012
Cytomegalovirus 2 (2.8 %) 11 (16.4 %) 5 (5.7 %) 0.007 0.458
BK virus 6 (8.3 %) 9 (13.4 %) 11 (12.6 %) 0.416 0.447
Urinary tract infection 5 (6.9 %) 6 (9.0 %) 14 (16.1 %) 0.758 0.090
Pneumonia 1 (1.4 %) 6 (9.0 %) 4 (4.6 %) 0.056 0.378
Sepsis 0 (0.0 %) 4 (6.0 %) 2 (2.3 %) 0.051 0.501
Abbreviations: MMF mycophenolate mofetil
agroup 1 vs. group 2
bgroup 1 vs. group 3
Table 4 Graft rejection
Low dose MMF Conventional dose MMF p1a p2b
Rituximab(+) Rituximab(+) Rituximab(−)
Group 1 (n = 72) Group 2 (n = 67) Group 3 (n = 87)
Hyperacute rejection 0 (0 %) 0 (0 %) 0 (0 %) - -
Acute cellular rejection 1 (1.4 %) 3 (4.5 %) 9 (10.3 %) 0.352 0.023
Antibody-mediated rejection 2 (2.8 %) 0 (0 %) 0 (0 %) 0.497 0.203
Chronic rejection 0 (0 %) 0 (0 %) 1 (0.6 %) - 1.000
Abbreviations: MMF mycophenolate mofetil
agroup 1 vs. group 2
bgroup 1 vs. group 3
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ABOi transplants (p = 0.527). Some studies have even
reported ABOi KT without using rituximab [12, 13].
There have been trials to minimize corticosteroid
exposure. Kato et al. [14] reported results of an early
steroid-withdrawal protocol in 130 patients using
cyclosporine, MMF and methyl-prednisolone with
basiliximab. The methyl-prednisolone was rapidly ta-
pered and withdrawn on post-transplant day 14. The
success rate of steroid withdrawal 12 months after
transplantation in recipients of ABOi was 44 %.
Galliford et al. [15] performed KT on 10 ABOi pa-
tients using 1 week of a steroids protocol with tacro-
limus and MMF. Patient- and allograft-survival were
100 % at 1-year post-transplantation in that study.
Three patients experienced antibody-mediated rejec-
tion within 2 weeks of transplantation, although they
were treated successfully. Oettl et al. [16] evaluated
late steroid withdrawal after ABOi KT in 15 patients
by performing protocol biopsies after 12 to 14 months.
If the biopsy did not show signs of rejection, steroid
was tapered and eventually stopped after 8 to
12 weeks. However, late steroid withdrawal was suc-
cessfully performed in only 5 of 11 patients. The
remaining 6 patients showed signs of mild acute re-
jection shortly after complete withdrawal or during
steroid tapering.
Our center adopted a low dose of rituximab
(200 mg/body) for ABOi KT at the end of 2009. The
safety of the early steroid withdrawal protocol was left
unproven, and it has been difficult to find data re-
garding the effectiveness of reduced maintenance im-
munosuppressant doses. However, in our previous
study, we observed that reduced doses of MMF in
rituximab-treated KT was safe [8]. CMV infection and
pneumonia occurred more often in rituximab-treated
KT. For management of infection, the dose of MMF
was reduced, but it did not increase the incidence of
acute rejection, and graft survival was 100 %. On the
basis of this study, we changed our protocol. Our
new protocol with lower dose of MMF showed good
graft function and reduced incidence of infectious
complications. It is a great burden to maintain long-
term immunosuppressant treatment with resultant
infectious risks in transplanted patients. Therefore, ef-
forts to minimize immunosuppressant levels are justi-
fied and will be continued.
Our present study had some limitations. All of our
study patients were Korean, and differences in phys-
ical and genetic factors between various ethnic groups
might affect the clinical results of our protocol for ri-
tuximab- and IL-2 receptor antibody- treated KT pa-
tients. In addition, the follow-up period was short,
Table 5 Serum creatinine levels (mg/dL)
Low dose MMF Conventional dose MMF p1a p2b
Rituximab(+) Rituximab(+) Rituximab(−)
Group 1 (n = 72) Group 2 (n = 67) Group 3 (n = 87)
Pre transplantation (72/67/87) 8.07 ± 2.82 8.51 ± 2.91 8.72 ± 3.58 0.371 0.213
After 1 month (72/66/87) 1.03 ± 0.60 1.21 ± 1.34 1.03 ± 0.33 0.313 0.930
After 3 months (71/55/86) 1.04 ± 0.26 1.17 ± 0.29 1.11 ± 0.30 0.012 0.153
After 6 months (71/48/71) 1.08 ± 0.27 1.21 ± 0.31 1.14 ± 0.31 0.012 0.181
After 1 year (49/39/48) 1.02 ± 0.26 1.16 ± 0.32 1.07 ± 0.29 0.033 0.388
After 2 years (6/4/15) 1.11 ± 0.20 0.98 ± 0.21 1.35 ± 0.67 0.338 0.397
Abbreviations: MMF mycophenolate mofetil
agroup 1 vs. group 2
bgroup 1 vs. group 3
Table 6 Mortality and malignancy
Low dose MMF Conventional dose MMF p1a p2b
Rituximab(+) Rituximab(+) Rituximab(−)
Group 1(n = 72) Group 2 (n = 67) Group 3 (n = 87)
Mortality 1 (1.4 %) 3 (4.5 %) 1 (1.1 %) 0.237 0.961
Graft failure 0 (0 %) 1 (1.5 %) 0 (0 %) 0.482 -
Malignancy 0 (0 %) 2 (3.0 %) 1 (1.1 %) 0.231 1.000
Abbreviations: MMF mycophenolate mofetil
agroup 1 vs. group 2
bgroup 1 vs. group 3
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necessitating a longer-term follow-up study in the fu-
ture for decisive clinical decision-making.
Conclusions
A protocol based on low doses of MMF decreases the in-
fection rate without increasing the incidence of rejection
or graft loss. This protocol might be useful for rituximab-
and IL-2 receptor antibody-treated KT, although a long-
term clinical study is necessary to validate these findings.
Abbreviations
ABOi: ABO incompatible; CMV: Cytomegalovirus; HLA: Human leukocyte
antigen; KT: Kidney transplantation; MMF: Mycophenolate mofetil.
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